New hope for transplant patients battling debilitating rejection disease
NCT ID NCT07476872
Summary
This early-stage study is testing an experimental drug called Gecacitinib for people with chronic graft-versus-host disease (cGVHD) that doesn't improve with standard steroid treatment. The trial will first find a safe dose and then see if the drug helps control the disease and improve symptoms. It is for adults who have had a stem cell transplant and are struggling with this difficult complication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CGVHD are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.